Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Robert R. McWilliams

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8199-5040; OpenAlex author ID A5006194799. Sources: ClinicalTrials.gov.

Their work

Papers
44 (first author 1, last author 4)
Trials
2 (principal investigator on 2)
Grants
0
Labs led
1
Collaborators
162
Papers, trials and grants by year

2008: 2 trials · 2009: none · 2010: none · 2011: 1 paper · 2012: 6 papers · 2013: 2 papers · 2014: 3 papers · 2015: 3 papers · 2016: 3 papers · 2017: none · 2018: 5 papers · 2019: 1 paper · 2020: 5 papers · 2021: 2 papers · 2022: 4 papers · 2023: 3 papers · 2024: 2 papers · 2025: 3 papers · 2026: 1 paper

Papers 44

  1. Spatial Configuration of Pancreatic Cancer Is Associated with Disease Recurrence after Neoadjuvant Therapy and Curative-Intent Resection. Co-author DOI 10.1158/1078-0432.ccr-25-4968↗
  2. Fatty acid synthase (FASN) inhibition cooperates with BH3 mimetic drugs to overcome resistance to mitochondrial apoptosis in pancreatic cancer. Co-author DOI 10.1016/j.neo.2025.101143↗
  3. Genomic and Immune Landscape of Pancreatic Ductal Adenocarcinoma Associated with Germline Pathogenic Variants in ATM. Co-author DOI 10.1158/1078-0432.ccr-24-4120↗
  4. Molecular KRAS ctDNA Predicts Metastases and Survival in Pancreatic Cancer: A Prospective Cohort Study. Co-author DOI 10.1245/s10434-025-17036-y↗
  5. Early vs conventional onset pancreatic ductal adenocarcinoma: analysis of surgical and oncologic outcomes in patients undergoing curative intent resection. Co-author DOI 10.1016/j.hpb.2023.09.010↗
  6. Molecular Characterization and Therapeutic Opportunities in KRAS Wildtype Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers16101861↗
  7. Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: a Phase I Dose Escalation and Expansio… Co-author DOI 10.1158/1078-0432.ccr-23-2993↗
  8. Efficacy of Immune Checkpoint Inhibition and Cytotoxic Chemotherapy in Mismatch Repair-Deficient and Microsatellite Instability-High Pancreatic Cancer: Mayo Cl… Co-author DOI 10.1200/po.22.00706↗
  9. Cytoreduction with Hyperthermic Intraperitoneal Chemoperfusion for Pancreatic Cancer with Low-Volume Peritoneal Metastasis: Results from a Prospective Pilot St… Co-author DOI 10.1245/s10434-022-12328-z↗
  10. Influence of Cancer Susceptibility Gene Mutations and ABO Blood Group of Pancreatic Cancer Probands on Concomitant Risk to First-Degree Relatives. Co-author DOI 10.1158/1055-9965.epi-21-0745↗
  11. Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study. Co-author DOI 10.1158/1078-0432.ccr-22-0308↗
  12. Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer. Co-author DOI 10.1245/s10434-021-10991-2↗
  13. FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.6004/jnccn.2022.7041↗
  14. The role of microbiome in pancreatic cancer. Co-author DOI 10.1007/s10555-021-09982-2↗
  15. Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000003284↗
  16. Clinical impact of celiac ganglia metastasis upon pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2019.11.003↗
  17. Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. Co-author DOI 10.1016/j.pan.2019.11.011↗
  18. Survival Benefit of Combination Chemotherapy in Elderly Patients With Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/coc.0000000000000708↗
  19. Effect of Germline Mutations in Homologous Recombination Repair Genes on Overall Survival of Patients with Pancreatic Adenocarcinoma. Last author DOI 10.1158/1078-0432.ccr-20-1788↗
  20. Role of Surgery and Perioperative Therapy in Older Patients with Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1634/theoncologist.2020-0086↗
  21. Risk of Different Cancers Among First-degree Relatives of Pancreatic Cancer Patients: Influence of Probands' Susceptibility Gene Mutation Status. Co-author DOI 10.1093/jnci/djx272↗
  22. Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer. Co-author DOI 10.1001/jama.2018.6228↗
  23. Prevalence of germ-line mutations in cancer genes among pancreatic cancer patients with a positive family history. Co-author DOI 10.1038/gim.2017.85↗
  24. CDKN2A Germline Rare Coding Variants and Risk of Pancreatic Cancer in Minority Populations. Co-author DOI 10.1158/1055-9965.epi-17-1065↗
  25. Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation. Co-author DOI 10.1200/po.17.00316↗
  26. The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation. Last author DOI 10.1371/journal.pone.0202272↗
  27. Genetic variations associated with gemcitabine treatment outcome in pancreatic cancer. Co-author DOI 10.1097/fpc.0000000000000241↗
  28. Risk Factors for Early-Onset and Very-Early-Onset Pancreatic Adenocarcinoma: A Pancreatic Cancer Case-Control Consortium (PanC4) Analysis. Co-author DOI 10.1097/mpa.0000000000000392↗
  29. Prevalence of Pathogenic Mutations in Cancer Predisposition Genes among Pancreatic Cancer Patients. Co-author DOI 10.1158/1055-9965.epi-15-0455↗
  30. BRCA2‐associated pancreatic cancer and current screening guidelines Last author DOI 10.1002/cncr.29447↗
  31. Phase II trial of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: a Mayo Clinic Phase II Consortium study. Last author DOI 10.1007/s10637-015-0246-2↗
  32. BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study. Co-author DOI 10.1038/gim.2014.153↗
  33. Inactivation of the transcription factor GLI1 accelerates pancreatic cancer progression. Co-author DOI 10.1074/jbc.m113.539031↗
  34. Axonal guidance signaling pathway interacting with smoking in modifying the risk of pancreatic cancer: a gene- and pathway-based interaction analysis of GWAS d… Co-author DOI 10.1093/carcin/bgu010↗
  35. Genes-environment interactions in obesity- and diabetes-associated pancreatic cancer: a GWAS data analysis. Co-author DOI 10.1158/1055-9965.epi-13-0437-t↗
  36. Polymorphisms in genes related to one-carbon metabolism are not related to pancreatic cancer in PanScan and PanC4. Co-author DOI 10.1007/s10552-012-0138-0↗
  37. Anti-diabetic medications and risk of pancreatic cancer in patients with diabetes mellitus: a systematic review and meta-analysis. Co-author DOI 10.1038/ajg.2013.7↗
  38. Aberrant signaling pathways in pancreatic cancer: a two compartment view. First author DOI 10.1002/mc.20827↗
  39. Pathway analysis of genome-wide association study data highlights pancreatic development genes as susceptibility factors for pancreatic cancer. Co-author DOI 10.1093/carcin/bgs151↗
  40. GLI1 inhibition promotes epithelial-to-mesenchymal transition in pancreatic cancer cells. Co-author DOI 10.1158/0008-5472.can-10-4621↗
  41. A replication study and genome-wide scan of single-nucleotide polymorphisms associated with pancreatic cancer risk and overall survival. Co-author DOI 10.1158/1078-0432.ccr-11-2856↗
  42. Factors influencing receptivity to future screening options for pancreatic cancer in those with and without pancreatic cancer family history. Co-author DOI 10.1186/1897-4287-10-8↗
  43. Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma. Co-author DOI 10.6092/1590-8577/913↗
  44. Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling. Co-author DOI 10.1038/ejhg.2010.198↗

Trials 2

  1. Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Stage IV Pancreatic Cancer Principal investigator NCT00577889↗
  2. Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer Principal investigator NCT00654160↗

Closest collaborators

The 25 strongest of 162 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mark Joseph Truty · 8 shared papers, 2020–2026 · strength 1.27
  2. Gloria M. Petersen · 18 shared papers, 2011–2022 · strength 1.15
  3. Amit Mahipal · 7 shared papers, 2020–2024 · strength 0.96
  4. Tanios Bekaii‐Saab · 7 shared papers, 2020–2024 · strength 0.94
  5. Sean Patrick Cleary · 6 shared papers, 2021–2025 · strength 0.94
  6. Wen Wee Ma · 7 shared papers, 2020–2024 · strength 0.93
  7. Cornelius A. Thiels · 5 shared papers, 2022–2026 · strength 0.93
  8. Michael L. Kendrick · 6 shared papers, 2020–2025 · strength 0.82
  9. Susanne Gray Warner · 4 shared papers, 2022–2025 · strength 0.70
  10. Ryan Michael Carr · 4 shared papers, 2020–2026 · strength 0.67
  11. Chunling Hu · 6 shared papers, 2016–2025 · strength 0.64
  12. Fergus Joseph Couch · 6 shared papers, 2016–2025 · strength 0.64
  13. Kari G. Rabe · 9 shared papers, 2011–2022 · strength 0.62
  14. Jennifer A. Yonkus · 4 shared papers, 2022–2025 · strength 0.62
  15. Travis Edward Grotz · 4 shared papers, 2022–2025 · strength 0.62
  16. Rondell Patrell Graham · 4 shared papers, 2021–2025 · strength 0.55
  17. Thorvardur Ragnar Halfdanarson · 4 shared papers, 2021–2024 · strength 0.52
  18. Martín E. Fernández-Zapico · 6 shared papers, 2012–2026 · strength 0.49
  19. Katrina Sophia Pedersen · 6 shared papers, 2011–2023 · strength 0.48
  20. Amro M. Abdelrahman · 3 shared papers, 2022–2025 · strength 0.44
  21. Roberto Alva‐Ruiz · 3 shared papers, 2022–2025 · strength 0.44
  22. Daniel D. Billadeau · 2 shared papers, 2025 · strength 0.41
  23. Christopher Leigh Hallemeier · 3 shared papers, 2021–2022 · strength 0.36
  24. Samuel O. Antwi · 4 shared papers, 2018–2022 · strength 0.35
  25. Aakash P. Desai · 2 shared papers, 2023–2024 · strength 0.34

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.